Retina

Pandemic highlights need for longer-lasting agents to reduce treatment burden in evolving field.

Investigators find value in screening for macular disease in preoperative evaluation

S.K. Steven Houston III, MD, shares how his practice has put to use recent retina innovations and adapted to accommodate the ever-changing operating room spacing and set-up in the current COVID-19 environment.

Megan Berkenstock, MD, assistant professor of ophthalmology at the Wilmer Eye Institute (Johns Hopkins University) speaks on the change in patient diagnoses and visit numbers by subspecialties in the weeks before and after the discovery of COVID-19 as well as the protocol needed to allow for the program's ambulatory surgery centers.

Pandemic is disrupting clinical facilities, putting individuals’ ocular health at risk

Ophthalmologists share what keeps them up at night in the ophthalmic profession amid the pandemic.

Research results can help ophthalmologists treating patients with macular edema

Investigators examine and analyze outcomes of aflibercept compared with laser treatment in patients

Ophthalmologists share their outlook for the current state and future of the ophthalmic profession, how coronavirus pandemic has altered the profession as well as how —now, more than ever — patient care remains a number one priority for ophthalmologists.

Retina specialists Caesar Luo, MD, of Bay Area Retina Associates (Walnut Creek, CA) and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.

The FDA this week granted the fourth Orphan Drug Designation for a novel gene therapy product candidate (OCU400, Ocugen Inc.) in the treatment of PDE6B gene mutation-associated retinal diseases.

Chronic cases can be difficult for retinal specialists, but treatment is satisfying.

Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."

Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.

Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.

Dilraj Grewal, MD, associate professor of ophthalmology at Duke Eye Center/ director of grading at the Duke Reading Center, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during the virtual 2020 ASRS meeting.

Investigators find treatment with EPO shows no effect on the development of ROP.

ASRS 2020 coverage: The Audacious Goals Initiative of the National Eye Institute is focused on developing noninvasive imaging advances to help patients with vision loss.

Canadian ophthalmologists receive updates on best practices amid coronavirus outbreak

Research finds automated segmentation software examines OCT scans

Physicians can discover, diagnose, document, treat diseases that might go undetected

Patient enrollment for the NORSE 2 clinical trial has been completed, with safety and efficacy data expected to be reported in the third quarter of 2021.

Overcoming protein deficiency in autosomal dominant optic atrophy

Subclinical lesions have been detected that are not apparent on other imaging platforms